Author:
Powers Benjamin J.,Coeytaux Remy R.,Dolor Rowena J.,Hasselblad Vic,Patel Uptal D.,Yancy William S.,Gray Rebecca N.,Irvine R. Julian,Kendrick Amy S.,Sanders Gillian D.
Publisher
Springer Science and Business Media LLC
Reference126 articles.
1. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335(8693):827–38.
2. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.[Erratum appears in Lancet. 2003 Mar 22;361(9362):1060]. Lancet. 2002;360(9349):1903–13.
3. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366(9502):2026–33.
4. Matchar DB, McCrory DC, Orlando LA, et al. Comparative Effectiveneness of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Antagonists (ARBs) for Treating Essential Hypertension. Comparative Effectiveness Review No. 10. (Prepared by Duke Evidence-based Practice Center under Contract No. 290-02-0025.) Rockville, MD: Agency for Healthcare Research and Quality. November 2007. Available at:
www.effectivehealthcare.ahrq.gov/reports/final.cfm
. Accessed October 31, 2010.
5. Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008;148(1):16–29.